Effects of mTOR inhibitor–related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients

We have previously described the use of sirolimus (SRL) as primary immunosuppression following heart transplantation (HT). The advantages of this approach include attenuation of cardiac allograft vasculopathy (CAV), improvement in glomerular filtration rate (GFR), and reduced malignancy. However, in some patients SRL may cause significant proteinuria. We sought to investigate the prognostic value of proteinuria after conversion to SRL. CAV progression and adverse clinical events were studied. CAV progression was assessed by measuring the Δ change in plaque volume (PV) and plaque index (PI) per year using coronary intravascular ultrasound. Proteinuria was defined as Δ urine protein ≥300 mg/24 h at 1 year after conversion to SRL. Overall, 137 patients were analyzed (26% with proteinuria). Patients with proteinuria had significantly lower GFR (P = .005) but similar GFR during follow‐up. Delta PV (P < .001) and Δ PI (P = .001) were significantly higher among patients with proteinuria after adjustment for baseline characteristics. Multivariate Cox regression analysis showed higher all‐cause mortality (hazard ratio 3.8; P = .01) with proteinuria but similar risk of CAV‐related events (P = .61). Our results indicate that proteinuria is a marker of baseline renal dysfunction, and that HT recipients who develop proteinuria after conversion to SRL have less attenuation of CAV progression and higher mortality risk.

[1]  G. Dellgren,et al.  Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study , 2020, Transplantation.

[2]  Byron H. Smith,et al.  Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation. , 2019, Journal of the American College of Cardiology.

[3]  J. Stypmann,et al.  Comparing everolimus‐based immunosuppression with reduction or withdrawal of calcineurin inhibitor reduction from 6 months after heart transplantation: The randomized MANDELA study , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  A. Karimpour-Fard,et al.  Elevated serum vascular endothelial growth factor and development of cardiac allograft vasculopathy in children. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[5]  W. Kremers,et al.  Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients. , 2018, Journal of the American College of Cardiology.

[6]  A. Yeung,et al.  Angiotensin-Converting Enzyme Inhibition Early After Heart Transplantation. , 2017, Journal of the American College of Cardiology.

[7]  J. F. Keane,et al.  Vascular endothelial growth factor A is associated with the subsequent development of moderate or severe cardiac allograft vasculopathy in pediatric heart transplant recipients. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  G. Ewald,et al.  Everolimus Versus Mycophenolate Mofetil in Heart Transplantation: A Randomized, Multicenter Trial , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  D. Mancini,et al.  Randomized Controlled Trial of Sirolimus Conversion in Cardiac Transplant Recipients With Renal Insufficiency , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  Charles M. Miller,et al.  An emerging population: kidney transplant candidates who are placed on the waiting list after liver, heart, and lung transplantation. , 2010, American Society of Nephrology. Clinical Journal.

[11]  F. Lehner,et al.  Biopsy‐Diagnosed Renal Disease in Patients After Transplantation of Other Organs and Tissues , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  M. Bailey,et al.  Late Onset Antibody-Mediated Rejection and Endothelial Localization of Vascular Endothelial Growth Factor Are Associated With Development of Cardiac Allograft Vasculopathy , 2008, Transplantation.

[13]  W. Kremers,et al.  Replacement of Calcineurin-Inhibitors With Sirolimus as Primary Immunosuppression in Stable Cardiac Transplant Recipients , 2007, Transplantation.

[14]  E. Letavernier,et al.  High sirolimus levels may induce focal segmental glomerulosclerosis de novo. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[15]  P. Beaune,et al.  Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. , 2006, Kidney international.

[16]  J. Kirklin,et al.  Increasing referral for renal transplant evaluation in recipients of nonrenal solid-organ transplants: a single-center experience. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[17]  G. Ewald,et al.  Tacrolimus with Mycophenolate Mofetil (MMF) or Sirolimus vs. Cyclosporine with MMF in Cardiac Transplant Patients: 1‐Year Report , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  J. Wetzels,et al.  Sirolimus‐Associated Heavy Proteinuria in a Renal Transplant Recipient: Evidence for a Tubular Mechanism , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  A. Pariente,et al.  Proteinuria Following a Switch from Calcineurin Inhibitors to Sirolimus , 2005, Transplantation.

[20]  H. Izzedine,et al.  Post-transplantation proteinuria and sirolimus. , 2005, The New England journal of medicine.

[21]  P. Armstrong,et al.  Renal Insufficiency and Heart Failure: Prognostic and Therapeutic Implications From a Prospective Cohort Study , 2004, Circulation.

[22]  R. Wolfe,et al.  Chronic renal failure after transplantation of a nonrenal organ. , 2003, The New England journal of medicine.

[23]  E. Tuzcu,et al.  Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. , 2003, The New England journal of medicine.

[24]  P. Ganz,et al.  EXPRESSION PATTERNS OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN HUMAN CARDIAC ALLOGRAFTS: ASSOCIATION WITH REJECTION , 2003, Transplantation.

[25]  M. Arias,et al.  The risk of cardiovascular disease associated with proteinuria in renal transplant patients. , 2002, Transplantation.

[26]  C. Mavroudis,et al.  Serum vascular endothelial growth factor as a surveillance marker for cellular rejection in pediatric cardiac transplantation. , 2002, Transplantation.

[27]  M. Sabbatini,et al.  Acute effects of rapamycin on glomerular dynamics: a micropuncture study in the rat. , 2000, Transplantation.

[28]  F. Waagstein,et al.  Predictors and evolution of renal function during 9 years following heart transplantation. , 2000, Journal of the American Society of Nephrology : JASN.

[29]  Y. Shyr,et al.  Long-term renal function in heart transplant recipients receiving cyclosporine therapy. , 1997, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[30]  W. Bennett,et al.  Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. , 1996, Transplantation.

[31]  N. Perico,et al.  Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. , 1991, Kidney international.